ECYT will be seen in 2015 as one of the great biotech opportunities that was deep under the radar of the investing community. They have a powerful and unique platform with loads of cash and a large pharma (Merck) which is paying to develop the technology and still providing half the profits to ECYT. They have a second payload that they own completely that is 25x more powerful then the one they licensed to Merck.
The stock is trading only 100K a day and has not moved much in 9 months while increasing data is coming out showing the power of their drug development program. This is a great opportunity to buy under $20/share and I see as a good possibility to be over $100/share by 2015
I agree - the current price shows no value for the tubulysin program (blockbuster with a prostate cancer targeting agent) or the inflammation program (this will take longer to develop clinically, being chronic conditions, but the potential is enormous). While the overall market scares me, there are a number of small biotechs like ECYT that are just beginning to show their value - the next few years will be interesting.
ECYT drugs target large markets with large unmet needs and MERCK as partner is funding development with substantial payments along the way. They have a load of cash 200 million and low burn rate. Vastly under the radar
I own over 100K and still buying. Once NSCLC Pahse 2b reports and ovarian phase 3 reports value of company with good results as expected (based on prior studies already reported) would warant a price at 10x present price ( see ARIA or PCYC as comparison but their drug covers greater patient population). Risk Reward is the best in Biotech. Way under the radar with less then 100k daily and a lot by computerized trading.